By Ana Sandoiu Fact checked by Isabel Godfrey New research presents a complex electronic device as a possible new, efficient, simple, and cost-effective way of detecting bladder cancer in its early stages and monitoring people living with bladder cancer. The American Cancer Society (ACS) estimate that bladder cancer will affect 80,470 people in the United States this year. About 17,670 deaths are...
Tag: <span>Bladder Cancer</span>
Post
New urine tests for bladder cancer may improve patient outcomes; reduce procedures, costs
by Medical College of Georgia at Augusta University Two new urine tests appear to accurately detect bladder cancer, determine its severity and detect its recurrence, investigators report. The tests look at activity and levels of V1, a gene variant upregulated in bladder cancer that dissolves natural sugars in the mucosal lining of the fist-sized bladder, making it more vulnerable to cancer. Investigators...
Post
New diagnostic technique reveals a protein biomarker that accurately differentiates bladder cancer from benign inflammation
Philadelphia, PA, February 12, 2019 – Label-free digital pathology using infrared (IR) imaging with subsequent proteomic analysis for bladder cancer (BC) has revealed the first protein biomarker (AHNAK2) for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose. A report in...
Post
Discovery could lead to higher immunotherapy response rates for bladder cancer patients
THE MOUNT SINAI HOSPITAL / MOUNT SINAI SCHOOL OF MEDICINE (New York, NY – August 29, 2018) — Mount Sinai researchers have discovered that a particular type of cell present in bladder cancer may be the reason why so many patients do not respond to the groundbreaking class of drugs known as PD-1 and PD-L1 immune checkpoint...
Post
New way to break cancer’s vicious cycle
University of Toronto researchers have uncovered why some cancers grow faster than others. The team led by Liliana Attisano, Professor in U of T’s Donnelly Centre for Cellular and Biomolecular Research, has identified a protein called NUAK2, which is produced by cancer cells to boost their proliferation and whose presence in tumours is associated with poor disease prognosis....
Post
Discovery of new biomarker could provide personalized treatment options for bladder cancer
Mount Sinai researchers use data science and genomics to help determine best treatment options for specific bladder cancers THE MOUNT SINAI HOSPITAL / MOUNT SINAI SCHOOL OF MEDICINE A potential new target for treatment has been identified in an aggressive form of bladder cancer, Mount Sinai researchers report in a recent study. Bladder cancers are...
Post
‘Game-changing’ urine test called UroMark could spare invasive procedure for bladder cancer patients and save NHS millions
UroMark can detect bladder cancer in 98% of cases, according to experts At present, people suspected of having bladder cancer undergo a cystoscopy Scientists responsible for the test believe that it could save the NHS about £25m A simple urine test designed to detect bladder cancer could spare patients an invasive procedure while also saving...
Post
Simple bladder cancer test can accurately predict the return of the disease for 80% of patients
Researchers have developed a machine which can detect a protein called TERT People suffering with bladder cancer often have high levels of TERT in their urine Detecting presence of TERT early could lead to earlier diagnosis and treatment Bladder cancer is the seventh most common cancer in the UK, statistics show A simple bladder cancer test developed...
Post
Drug based on malaria protein shows promise against treatment-resistant bladder cancer
A new study shows that a drug derived from a protein found in the malaria parasite stopped chemotherapy-resistant bladder cancer tumors growing in mice. The researchers say that the finding could lead to much-needed new treatments for cases of bladder cancer that do not respond to standard therapy. Researchers believe that the study findings could...
Post
FDA To Speed Up Review Of Roche Tecentriq As Immunotherapy Treatment For Bladder Cancer
Swiss pharmaceutical company Roche has announced that U.S. health regulators have agreed to grant priority review to its Tecentriq immunotherapy treatment for a type of bladder cancer. In a statement, the drug company said that the U.S. Food and Drug Administration has accepted its Biologics License Application, or BLA, and agreed to priority-review the treatment. Tecentriq Tecentriq (atezolizumab)...